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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A324usually shows higher levels in obese patients. Leptin has proin-
ﬂammatory effects and has been implicated in OA physiopathology.
Objective: To evaluate the relationship between body fat content with
the amount of synovial ﬂuid as a surrogate marker of inﬂammation and
with levels of synovial ﬂuid leptin in knee OA.
Methods: Patients aged 50 years or more with symptomatic osteo-
arthritis of the knee and joint effusion, Kellgren-Lawrence II-III. Dem-
ographics, disease duration and percentage of body fat (PBF) were
assessed. Percentage of body fat was determined by bio-electrical
impedance. Knee ultrasound (US) was performed evaluating and
measuring the presence of effusion and at the suprapatellar midline.
After US measurement joint aspiration was performed; all patients
were evaluated approximately at the same time of the day. Synovial
leptin levels were analyzed using a Human leptin ELISA kit (Bio-
compare, California, USA).
Results: Seventy consecutive female patients with symptomatic knee
OA and Kellgren-Lawrence II-III were included, age 65 ±7.8 years, dis-
ease duration of symptoms 66 ±49.5 mo (12-200). Mean BFP was 42.34
±5.11%. Patients were categorized into two groups based on BFP so that
those with levels above the mean and median values (n¼ 36) were
compared with the rest of the sample (n¼34). Mean synovial ﬂuid
measurement was 9.59 ±2.79 mm. Mean level of leptin in synovial ﬂuid
was 76.76 ±38.66 ng/mL. Patients in the higher BFP group had similar
amount of synovial effusion compared with those without such a high
percentage (9.4 ±2.4 vs. 9.75 ±3.2 mm). However, patients with BFP
above the mean and median values showed signiﬁcantly higher syno-
vial leptin levels than those with values below (88.47 ±46.8 vs. 60.24
±19.5 ng/mL, p <0.005).
Conclusions: Higher synovial leptin levels were observed in patients
with the highest body fat percentage as measured by bio-electrical
impedance. On the other hand, synovial effusion did not appear to be
linked to body fat content, indicating that body fat could be more
related to metabolic abnormalities than to clinical signs of inﬂamma-
tion.
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Purpose: Sex has a signiﬁcant effect on osteoarthritis (OA) prevalence
and severity, and women with OA often report greater pain than men
with OA. Pain is the principal driver of health care use in this pop-
ulation. Importantly, there is a connection between pain and inﬂam-
mation. While OA has not traditionally been considered a systemic joint
disease, evidence suggests that systemic factors may play a contributing
role in its pathogenesis and symptoms. The presence of multiple
symptomatic joints among many with OA further suggests potentially
underlying systemic mechanisms. Higher systemic concentrations of C-
reactive protein (CRP) among OA populations compared to controls
have been reported (CRP is a marker of inﬂammation), and a recent
review suggested low-grade inﬂammation may play a greater role in
symptoms than radiographic changes in OA. Sex differences in systemic
inﬂammation may explain sex differences in OA symptoms. However, it
may also be that for similar levels of inﬂammation, women report worse
pain than men. In this study, we investigated the association between
serum levels of CRP and the extent of painful joint involvement among
individuals with end stage hip/knee OA, and whether the association
differs between sexes.
Methods: Serum concentrations of CRP and cartilage oligomeric matrix
protein (COMP- a proxy for disease burden) were determined by ELISA
in 203 patients (115 females, 88 males) scheduled for total hip or knee
replacement surgery for OA. Individuals reporting inﬂammatory
arthritis were excluded. Patients completed a health questionnaire, and
indicated on a homunculus all joints that were painful/problematic on
most days for at least a month in the past 12 months. A count (not
including the surgical joint) was developed (range: 0 to 21). Also elicited
were age, sex, height and weight (used to calculate body mass index(BMI)), and comorbidities. Negative binomial regression was used to
investigate the association between painful joint count (model out-
come) and serum CRP concentrations, adjusting for age, sex, BMI,
comorbidity count and serum COMP concentration. An interaction
between sex and these biomarkers was tested. In a sensitivity analysis,
all individuals reporting conditions associated with metabolic syn-
drome were excluded from analysis (high blood pressure, diabetes,
heart disease and high cholesterol). For regression analyses, concen-
tration values were log transformed.
Results: Mean age: 66 years among women (>96% were 50), 64
among men. Women had higher mean joint count (4.6 vs 2.5, p<0.001;
4þ joints reported by 42% women, 28%men). 51% of womenwere obese
vs 36% in men (p¼0.06). Median CRP concentration was higher in
women (18.7 mg/ml vs 9.3, p¼0.003). From adjusted analyses, the effects
of both CRP and COMP were modiﬁed by sex (interaction terms:
p<0.001 and ¼0.016, respectively). Increasing concentration of CRP was
associated with greater painful joint burden among women, but not
men (Count ratio (CR) of interaction term: 1.4 (95% CI: 1.2, 1.6); main
effect: 0.9 (0.8, 1.0)). Results from the sensitivity analysis were con-
sistent (CR of interaction: 1.5 (1.1, 1.9); main effect: 0.81 (0.6, 1.0).
Conclusions: This work suggests that there may be a dose-response
association between painful joint burden in OA and systemic inﬂam-
mation, and it appears the association is sex-speciﬁc. These ﬁndings
create a potential opportunity to better risk-stratify women and men
with OA pain, with a goal to tailoring assessment, treatment, and/or
education strategies to optimize OA outcomes. In addition, given that
high systemic concentration of CRP has been identiﬁed as a risk factor
for diabetes and cardiovascular disease onset, these ﬁndings suggest
that those with greater joint burden may be an OA subgroup at greater
risk of comorbid disease onset, particularly women.
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Purpose: NSAIDs are frequently prescribed for the management of OA
pain. Investigational, low-dose SoluMatrix® meloxicam, manufactured
using SoluMatrix Fine Particle TechnologyTM, is being developed for
management of osteoarthritis pain, providing lower systemic exposure
than current commercially available meloxicam drug products to
potentially minimize the risk of NSAID dose-related adverse events
(AEs). Clinical studies have evaluated the pharmacokinetics (PK), efﬁ-
cacy, and safety of low-dose SoluMatrix meloxicam.
Methods: A phase 1 pharmacokinetic 4-period, 4-sequence crossover
study in healthy adults aged 18 to 55 years evaluated the PK properties
and safety of single doses of SoluMatrix meloxicam 5 mg (under fasted
conditions), SoluMatrix meloxicam 10 mg (under fasted and fed con-
ditions), and conventional meloxicam 15-mg tablets (Mobic®; Boeh-
ringer Ingelheim; under fasted conditions). Blood samples for PK
assessment were collected pre-dose through 96 h post-dose. Separately,
a phase 3 randomized, double-blind, placebo-controlled study enrolled
adults 40 years of age with radiographically conﬁrmed (Kellgren-
Lawrence grade II-III) hip or knee OA. Eligible patients were chronic
NSAID and/or acetaminophen users with a baseline WOMAC pain
subscale score 40 mm (based on 100-mm Visual Analog Scale) and a
documented OA pain ﬂare (15-mm increase in WOMAC pain subscale
score following washout of prior analgesics). Patients (N ¼ 403) were
randomized to receive once-daily treatment with SoluMatrix melox-
icam 5mg (n¼ 139), SoluMatrix meloxicam 10mg (n¼ 130), or placebo
(n ¼ 134). The primary efﬁcacy parameter was the mean change from
baseline in WOMAC pain subscale score at week 12.
Results: In the PK study, 28 participants were enrolled and 25 partic-
ipants completed the study. SoluMatrix meloxicam 10 mg attained
similar mean peak plasma meloxicam levels ± SD compared with con-
ventional meloxicam 15-mg tablets (1.25±0.25 mg/mL vs 1.29±0.42 mg/
mL, respectively; under fasted conditions; Table). Both SoluMatrix
meloxicam 5 mg and 10 mg achieved a more rapid median time to peak
plasma meloxicam levels under fasted conditions than conventional
